Delivery Order SPE2DB22D1002-SPE2DB25FLFY1
- Not listed
- The Defense Logistics Agency awarded a $6,165.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units. The contract, issued on July 22, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units valued at $6,165.34, with a completion deadline of July 23, 2025. This firm fixed-price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. Benlysta (belimumab) is a monoclonal antibody therapy used to treat systemic lupus erythematosus, and the auto-injector formulation facilitates...
- The Defense Logistics Agency awarded a delivery order valued at $18,496.02 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injectors. The contract, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, utilizes firm fixed-price pricing with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 28, 2025, with completion expected by September 19, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and represents a competitive award to the pharmaceutical distributor. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $55,488.06 for Benlysta 200 mg/ml auto-injectors on September 17, 2025, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $12,330.68 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector pharmaceutical supply. The contract, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL auto-injector on August 19, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 10, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified vendors in the...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 25, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $18,496.02 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector pharmaceutical product. This competitively awarded, firm fixed-price contract was executed on July 15, 2025, with an ultimate completion date of August 5, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLFY1Delivery Order
The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of August 27, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. As a child delivery order under a larger contract vehicle, this award leverages AmerisourceBergen's established relationship with DLA to supply pharmaceutical products to federal healthcare systems. This delivery order is issued under AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. That prime vehicle serves as a global pharmaceutical support contract enabling the company to supply a wide range of medications and medical supplies to support military healthcare programs worldwide. Benlysta (belimumab) is a biologic immunosuppressant used to treat systemic lupus erythematosus, and the auto-injector formulation facilitates self-administration for military personnel and veterans requiring this specialized therapeutic treatment.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 8/6/25 |